Log in to search using one of your social media accounts:

 

New clinical trial explores combining immunotherapy and radiation for sarcoma patients
(University of Maryland Medical Center) University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

NantCell takes on troubled CytRx chemotherapeutic
NantCell, one of controversial biotech entrepreneur Patrick Soon-Shiong’s many businesses, said last week that it inked a deal to acquire CytRx‘s (NSDQ:CYTR) aldoxorubicin cancer drug. The compound has faced several obstacles in clinical trials, including when it missed the primary endpoint of a late-stage clinical trial, failing to help patients with second-line soft tissue sarcoma in a significant way compared to a control therapy. Get the full story at our sister site, Drug Delivery Business News. The post NantCell takes on troubled CytRx chemotherapeutic appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Biotech Drug-Device Combinations Mergers & Acquisitions Oncology Pharmaceuticals Wall Street Beat cytrx nantcell Source Type: news

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin. (Source: CancerNetwork)
Source: CancerNetwork - July 22, 2017 Category: Cancer & Oncology Authors: Sant P. Chawla, MD Tags: Sarcoma Source Type: news

Activity of PD-1 Inhibitor Limited in Soft-Tissue Sarcomas
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Sarcoma Source Type: news

Coughing and constipation? You could be suffering from THIS rare whole-body cancer
COUGHING and constipation are two of the symptoms of soft tissue sarcomas - a group of rare cancers that can appear anywhere in the body. (Source: Daily Express - Health)
Source: Daily Express - Health - July 5, 2017 Category: Consumer Health News Source Type: news

Soft Tissue Sarcoma Differences: Therapeutic Implications Soft Tissue Sarcoma Differences: Therapeutic Implications
Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors, researchers report.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 4, 2017 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Development Program Can Support Approval, No New Studies Requested NDA Submission by CytRx Being Prepared Conference Call on April 19, 2017 at 8:30 AM EDT/ 5:30 AM PDT LOS ANGELES, April 19, 2017 -- (Healthcare Sales & Marketing Network) -- CytRx... Biopharmaceuticals, Oncology, FDA CytRx, aldoxorubicin, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2017 Category: Pharmaceuticals Source Type: news

Saving Arms and Legs in Advanced Soft Tissue Sarcomas Saving Arms and Legs in Advanced Soft Tissue Sarcomas
In patients with soft tissue sarcoma facing amputation of an arm or a leg, regional chemotherapy with isolated limb infusion treats local disease without affecting survival.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 22, 2017 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

A 5-Question Quiz on Sarcoma
Are you up to date on adverse prognostic factors for Ewing sarcoma? Do you know the latest drug approved for metastatic soft-tissue sarcoma? Test your knowledge on sarcoma in our latest quiz. (Source: CancerNetwork)
Source: CancerNetwork - February 5, 2017 Category: Cancer & Oncology Authors: Debra Hughes Tags: Quiz Source Type: news

Common heart drug repurposed to treat rare cancer in Europe
A drug that's commonly used to treat high blood pressure is being repurposed for a rare tissue cancer in Europe. The medication, named propranolol, was recently granted Orphan Drug Designation by the European Commission (EC). The designation signifies that the EC supports the use of a drug to treat patients because of its significant benefit to those living with a rare disease - in this case, soft tissue sarcoma. (Source: World Pharma News)
Source: World Pharma News - January 17, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New Cancer Drug Approvals From 2016
Chemotherapy is one of the most powerful tools we have to treat cancer, and research continues to find new chemotherapy drugs as well as new uses for existing ones. At the same time, newer types of drugs are continually being developed that work in different ways to attack cancer cells.They include targeted therapy, which aims to more precisely identify cancer cells while doing less damage to normal cells, and immunotherapy, which uses the body’s own immune system to help find and destroy cancer.Before any new drug can be sold in the United States, it has to go through an approval process by the Food and Drug Adminis...
Source: American Cancer Society :: News and Features - December 26, 2016 Category: Cancer & Oncology Tags: Advanced Cancer Source Type: news

Combo of cancer drugs shows promise against some tumors
HealthDay News Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 2, 2016 Category: Consumer Health News Source Type: news

Drug Combo Shows Promise Against Some Soft Tissue Tumors
FRIDAY, Dec. 2, 2016 -- Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. These cancers of soft tissues such as fat, muscles, blood vessels, tendons and ligaments are rare, but... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 2, 2016 Category: Journals (General) Source Type: news

Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug
Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 2, 2016 Category: Science Source Type: news

Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine
(ECCO-the European CanCer Organisation) Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Professor Antoine Italiano told the 28th EORTC-NCI-AACR Symposium that combining GDC-0575 with gemcitabine, a cancer-killing drug that is already used for treating sarcomas, proved remarkably effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2016 Category: Cancer & Oncology Source Type: news

Eli Lilly secures conditional marketing authorisation for olaratumab injection with doxorubicin
The European Commission (EC) has granted conditional marketing authorisation for Eli Lilly and Company ’s (LLY) olaratumab injection of 10mg/ml in combination with doxorubicin, to treat adults with advanced soft tissue sarcoma (STS) who are not suited… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 14, 2016 Category: Pharmaceuticals Source Type: news

Regorafenib Improves PFS in Non-Adipocytic Soft-Tissue Sarcoma
A phase II trial found that the multikinase inhibitor regorafenib has clinical activity and offers improved progression-free survival in certain types of advanced soft-tissue sarcoma. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news

PharmaMar shows new clinical data on Yondelis ® and lurbinectedin at ESMO 2016
(Pharmamar) During this congress, PharmaMar will inform in an oral session the results of its Phase II clinical trial with lurbinectedin in patients with BRCA 1/2 metastatic breast cancer.A prospective randomized phase III comparing trabectedin versus the best supportive care in patients with pretreated advanced soft tissue sarcoma(T-SAR trial) will be presented in an oral session by the French Sarcoma Group. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 5, 2016 Category: Global & Universal Source Type: news

Adding Palifosfamide Fails to Improve Survival in Metastatic Sarcoma
The addition of palifosfamide to doxorubicin failed to improve survival in a phase III trial of patients with metastatic soft-tissue sarcoma. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news

EU Panel Likes Breast Cancer Drug, Two Others EU Panel Likes Breast Cancer Drug, Two Others
Drugs for metastatic breast cancer, soft tissue sarcoma, and multiple myeloma all got a recommendation for approval.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 16, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

New Mesothelioma Drug Discovered in Sea Squirt Toxin
A unique drug derived from the Caribbean sea squirt shows impressive effectiveness in stopping the growth of mesothelioma tumor cells. Researchers at the Medical University of Vienna in Austria discovered that trabectedin, a toxin the coral-like animal uses against predators, might soon be applied in the treatment of mesothelioma. “It has looked very promising to this point,” Walter Berger, group leader at the Institute of Cancer Research, University of Vienna, told Asbestos.com. “It’s a fascinating new substance — from its origins to its mode of action.” A European pharmaceutical compan...
Source: Asbestos and Mesothelioma News - August 30, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: mesothelioma treatment sea squirt cancer treatment sea squirt trabectedin toxin sea toxin for cancer trabectedin for mesothelioma Source Type: news

Alisertib Shows Promise in Soft-Tissue Sarcoma
Alisertib yielded promising progression-free survival in advanced/metastatic soft-tissue sarcoma patients, though it did not meet its primary response rate endpoint. (Source: CancerNetwork)
Source: CancerNetwork - August 16, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news

Arkansas Hospice Adds Physician Robin Devan (Movers & Shakers)
Dr. Robin Devan of Little Rock has joined Arkansas Hospice as a physician for the central Arkansas area. Devan has served as an assistant professor of palliative care at the Winthrop P. Rockefeller Cancer Institute and the University of Arkansas for Medical Sciences Hospital, as well as director of the UAMS Adult Sickle Cell Clinical Program. Eric Burgener and Turner Sibley, physical therapists at Conway Regional Therapy Center-Scherman Heights, have been awarded board certification in orthopedics through the American Board of Physical Therapy Specialties. Burgener is certified in workers’ comp rehabilitation, while...
Source: Arkansas Business - Health Care - August 8, 2016 Category: American Health Source Type: news

Scientists Trace Origin Cell of Bone and Soft Tissue Tumors, Test Drug Target
Contact: Samiha Khanna Phone: 919-419-5069 Email: samiha.khanna@duke.edu https://www.dukehealth.org EMBARGOED FOR RELEASE until 12 p.m. (ET) on Thursday, July 14, 2016 DURHAM, N.C. -- Scientists at Duke Health are part of a team that has discovered a type of cell surrounding blood vessels can also serve as a starting point for sarcoma, a form of cancer that occurs in bones and connective tissues. The findings, made through studies of mice, offer insights that could aid in the development of potential new treatments for the rare but devastating cancer, which has 15,000 new diagnoses annually in the U.S. In an article to be ...
Source: DukeHealth.org: Duke Health Features - July 14, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news

What Are The Most Common Pediatric Cancers?
Discussion Cancer occurs in all ages including children. Fortunately cancer is much less common in the pediatric age group accounting for
Source: PediatricEducation.org - July 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Unprecedented, But Puzzling, Results in Advanced SarcomaUnprecedented, But Puzzling, Results in Advanced Sarcoma
In soft tissue sarcoma, the investigational antibody olaratumab improved overall survival by a large margin and progression-free survival by a considerably smaller margin, which is unusual. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 14, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chemo for Adult Sarcomas: Murky Data and Experts' InsightsChemo for Adult Sarcomas: Murky Data and Experts' Insights
The paucity of data on the relative benefits of chemotherapy in adult soft-tissue sarcomas muddies the clinical decision-making waters, say sarcoma experts, who offer some advice, anyway. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 27, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

[Perspective] The cancer predisposition revolution
Studies of rare cancer predisposition syndromes often lead to the identification of genes critical to carcinogenesis. In 1969, Li and Fraumeni described a constellation of various cancers in the family members of four unrelated children who were diagnosed with soft tissue sarcomas (1). They posited that the cancers best fit an autosomal dominant pattern of inheritance, attributable to a genetic defect. At that time, cancer was not generally thought of as a genetic disease. Their hypothesis set the stage for establishing germline mutations in the tumor suppressor gene TP53 as the underlying genetic event in Li-Fraumeni synd...
Source: ScienceNOW - May 26, 2016 Category: Science Authors: David Malkin Tags: Cancer Source Type: news

MSK surgeons present strategies for increasing survival in soft tissue sarcoma patients
(American Association for Thoracic Surgery) In a presentation at the 96th AATS Annual meeting, Neel P. Chudgar, M.D., from the Department of Surgery at Memorial Sloan Kettering Cancer Center presents survival data and prognostic factors based on a large, single-institution database of STS patients who have undergone pulmonary metastasectomy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2016 Category: Cancer & Oncology Source Type: news

FDA Grants Priority Review For Lilly's Olaratumab, An Investigational Medicine For Advanced Soft Tissue Sarcoma
INDIANAPOLIS, May 4, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the biologics license application (BLA) for olaratumab, a PDGFRα... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 4, 2016 Category: Drugs & Pharmacology Source Type: news

Radiation may help after surgery for 'soft-tissue' cancers
HealthDay News Older patients with a type of cancer called soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do.. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 14, 2016 Category: Consumer Health News Source Type: news

Radiation May Help After Surgery for 'Soft-Tissue' Cancers
Biggest benefit was seen in people over 65, research suggests Source: HealthDay Related MedlinePlus Pages: Radiation Therapy, Soft Tissue Sarcoma, Surgery (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 14, 2016 Category: Consumer Health News Source Type: news

Radiation May Help After Surgery for 'Soft-Tissue' Cancers
THURSDAY, April 14, 2016 -- Older patients with a type of cancer called soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do, a new study suggests. The results might change the way older patients are... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 14, 2016 Category: Journals (General) Source Type: news

Radiation improves survival in older patients with soft tissue sarcomas
Radiation therapy following surgery benefits older patients more than their younger counterparts, researchers report, a surprising finding that could change the way some patients are treated for soft tissue sarcomas (STS). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 11, 2016 Category: Science Source Type: news

Eribulin Makes 3: Changing Treatment Landscape for SarcomaEribulin Makes 3: Changing Treatment Landscape for Sarcoma
After a 40-year dearth of new treatments, three new drugs have been approved for soft-tissue sarcomas. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 17, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Halaven (Eribulin) for Liposarcoma
By Stacy SimonThe US Food and Drug Administration (FDA) has approved the chemotherapy drug Halaven (eribulin) to treat liposarcoma, a type of soft tissue sarcoma. Halaven is already approved to treat advanced breast cancer. The new use is for people with liposarcoma who have already been treated with anthracycline-based chemotherapy and have tumors that cannot be removed through surgery or have spread to other parts of the body. This is the first drug approved for people with liposarcoma that has shown improvement in overall survival.Liposarcomas are cancerous tumors of fat tissue. They can develop anywhere in the body, bu...
Source: American Cancer Society :: News and Features - January 30, 2016 Category: Cancer & Oncology Tags: Sarcoma - Adult Soft Tissue Cancer Source Type: news

FDA Approves Halaven (eribulin mesylate) for the Treatment of Liposarcoma
January 28, 2016 -- The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 28, 2016 Category: Drugs & Pharmacology Source Type: news

FDA approves first drug to show survival benefit in liposarcoma
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 28, 2016 Category: American Health Source Type: news

FDA approves first drug to show survival benefit in liposarcoma
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). (Source: World Pharma News)
Source: World Pharma News - January 28, 2016 Category: Pharmaceuticals Tags: Featured Food and Drug Administration (FDA) Regulatory Affairs Source Type: news

Early Trial Shows Injectable Agent Illuminates Cancer During Surgery
Contact: Samiha KhannaPhone: 919-419-5069Email: samiha.khanna@duke.eduhttps://www.dukemedicine.org EMBARGOED FOR RELEASE until 2 p.m. (ET) Wednesday, Jan. 6, 2016 DURHAM, N.C. -- Doctors at Duke Medicine have tested a new injectable agent that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon’s ability to locate and remove all of a cancerous tumor on the first attempt. The imaging technology was developed through collaboration with scientists at Duke, the Massachusetts Institute of Technology (MIT) and Lumicell Inc. According to findings published January 6 in Science Translational Medicin...
Source: DukeHealth.org: Duke Health Features - January 6, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news

Immune begins Phase II CMB305 trial to treat soft tissue sarcoma
Immune Design has started a Phase II trial of CMB305, a combination cancer immunotherapy for soft tissue sarcoma. (Source: Drug Development Technology)
Source: Drug Development Technology - November 12, 2015 Category: Pharmaceuticals Source Type: news

FDA clears J&J's chemotherapy for certain soft tissue sarcomas
(Reuters) - The U.S. Food and Drug Administration said it approved Johnson & Johnson's chemotherapy to treat specific soft-tissue sarcomas (STS) that have spread to other parts of the body or cannot be removed by surgery. (Source: Reuters: Health)
Source: Reuters: Health - October 23, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves New Option for Soft-Tissue Sarcoma
(MedPage Today) -- Trabectedin slowed disease progression versus dacarbazine (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 23, 2015 Category: American Health Source Type: news

FDA Approves Trabectedin for Two Soft Tissue SarcomasFDA Approves Trabectedin for Two Soft Tissue Sarcomas
Researchers saw no improvement in overall survival in the pivotal US trial, but there are explanations for that. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

New Drug Approved for Soft-Tissue Cancer
Disease most often affects head, neck, extremities and torso Source: HealthDay Related MedlinePlus Pages: Medicines, Soft Tissue Sarcoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 23, 2015 Category: Consumer Health News Source Type: news

FDA approves new therapy for certain types of advanced soft tissue sarcoma
The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who previously received chemotherapy that contained anthracycline. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 23, 2015 Category: American Health Source Type: news

YONDELIS® receives marketing approval in Japan for the treatment of STS
(Pharmamar) PharmaMar announced that its partner in Japan, Taiho Pharmaceutical, received marketing approval for YONDELIS® (trabectedin) by the Japanese Minister of Health, Labour and Welfare for the treatment of patients with soft tissue sarcoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2015 Category: Cancer & Oncology Source Type: news

PharmaMar shows new data for YONDELIS and PM1183 in soft tissue sarcoma and solid tumors at ECC 2015
(Pharmamar) PharmaMar showcases new data for anticancer compounds in soft tissue sarcoma and advanced solid tumors at the European Cancer Congress 2015 in Vienna. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2015 Category: Cancer & Oncology Source Type: news

Pazopanib improves progression-free survival without impairing quality of life
In patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life, research shows. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 6, 2015 Category: Science Source Type: news